Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration

Retina

Volumn 27, Issue 4, 2007, Pages 439-444

  Emerson, M Vaughn ^a   Lauer, Andreas K ^a   Flaxel, Christina J ^a   Wilson, David J ^a   Francis, Peter J ^a   Stout, J Timothy ^a   Emerson, Geoffrey G ^a   Schlesinger, Thomas K ^a   Nolte, Susan K ^a   Klein, Michael L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Mail Code: CEI   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Optical coherence tomography

Indexed keywords

BEVACIZUMAB;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG RESPONSE; FEMALE; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PROGNOSIS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 34247218633     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31804b3e15     Document Type: Article

References (12)

1. Eye Diseases Prevalence Research Group. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
2. Klein R, Klein BEK, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the Multi-ethnic Study of Atherosclerosis. Arch Ophthalmol 2006;113:373-380.
3. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-918.
4. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macula degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198-207.
5. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
6. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:1805-1816.
7. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633-642.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
9. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
10. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
11. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390.
12. Fung AE, Rosenfeld PJ, Reichel EZ. The International Intravitreal Avastin Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.